FGFR2 and cholangiocarcinoma: Most recently, the next-generation FGFR1-4 inhibitor futibatinib has also shown activity and a tolerable safety profile in the treatment of advanced cholangiocarcinoma with FGFR-2 fusions or rearrangements.